TC

04/03/2021 14:54

Junshi Bio (01877) initiates rolling submission of BLA

   Shanghai Junshi Biosciences Co., Ltd. (01877) said its subsidiary  TopAlliance Biosciences, Inc. has initiated the rolling submission of its Biologics License Application (BLA) for toripalimab (product code: TAB001/JS001) with the US Food and Drug Administration (the FDA) for the treatment of recurrent or metastatic nasopharyngeal carcinoma.
  Toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing in China. More than thirty company-sponsored clinical studies covering more than fifteen indications have been conducted globally, including in China and the United States.

etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情

人氣文章
財經新聞
評論
專題
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

道教符箓解析:符咒能醫百病可驅鬼?功效、製作、用法、顏色代表咩?

帶你探索全新主頁!輕鬆探索精選資訊!

etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎